In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Over 70% of patients with ovarian cancer are diagnosed at an advanced stage, often presenting with large volumes of ascites. This ascites fluid not only supports the spread of cancer throughout ...

High-risk advanced ovarian cancer patients showed marginal survival ... with high-risk prognostic factors, such as stage III disease and >1 cm residual disease, stage IV, or unresectable disease.